On Tuesday, U.S. District Judge Brian Cogan in New York dismissed key consumer claims in the multidistrict litigation against ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

The lawsuits arose after recipients of GSK’s heartburn drug Zantac claimed it caused cancer. Chief executive Emma Walmsey said the move to settle around 80,000 lawsuits across the US ...

I had last written about GSK earlier this month, following news that it had finally settled a majority of the long-pending cases against its heartburn medication drug Zantac, which was alleged to ...

Despite recent resolution to most of its cancer claims related to its heartburn drug Zantac in the U.S. and an attractive valuation, “we see limited potential upside in 2025 pipeline catalysts ...

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in ...

Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the United States, claiming that its discontinued version of the heartburn drug Zantac caused cancer.

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

Guggenheim Securities downgraded GSK to neutral from buy on Thursday after the British drugmaker reported a ~2% decline in ...